A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings
Open Access
- 24 June 2015
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 2 (3), ofv095
- https://doi.org/10.1093/ofid/ofv095
Abstract
Background. Existing data on anthropomorphic changes in resource-limited settings primarily come from observational or cross-sectional studies. Data from randomized clinical trials are needed to inform treatment decisions in these areas of the world. Methods. The AIDS Clinical Trials Group Prospective Evaluation of Antiretrovirals in Resource-Limited Settings (PEARLS) study was a prospective, randomized evaluation of the efficacy of emtricitabine/tenofovir + efavirenz (FTC/TDF + EFV) vs lamivudine/zidovudine + efavirenz (3TC/ZDV + EFV) for the initial treatment of human immunodeficiency virus (HIV)-1-infected individuals from resource-diverse settings. Changes in anthropomorphic measures were analyzed using mixed-effect models for repeated measurements, using all available measurements at weeks 48, 96, and 144. Intent-to-treat results are presented; as-treated results were similar. Results. Five hundred twenty-six participants were randomized to FTC/TDF + EFV, and 519 participants were randomized to 3TC/ZDV + EFV. Significantly greater increases from baseline to week 144 were seen among those randomized to FTC/TDF + EFV vs 3TC/ZDV + EFV in all measures except waist-to-hip ratio, with the following mean changes: weight, 4.8 vs 3.0 kg; body mass index, 1.8 vs 1.1 kg/m2; mid-arm, 1.7 vs 0.7 cm; waist, 5.2 vs 4.3 cm; hip, 3.8 vs 1.4 cm; and mid-thigh circumference, 3.1 vs 0.9 cm. There were 7 clinical diagnoses of lipoatrophy in the 3TC/ZDV + EFV arm compared with none in the FTC/TDF + EFV arm. The proportion of overweight or obese participants increased from 25% (week 0) to 42% (week 144) for FTC/TDF + EFV and from 26% to 38% for 3TC/ZDV + EFV. Conclusions. Our findings support first-line use of FTC/TDF + EFV in resource-limited settings and emphasize the need for interventions to limit weight gain among overweight or obese HIV-infected participants in all settings.Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (UM1 AI068634, UM1 AI068636, UM1 AI106701)
- The National Institute of Aging
- National Institutes of Health (K23AG050260)
- Gilead Sciences, Inc
- GlaxoSmithKline
This publication has 35 references indexed in Scilit:
- High prevalence of obesity among women who enrolled in HIV prevention trials in KwaZulu-Natal, South Africa: healthy diet and life style messages should be integrated into HIV prevention programsBMC Public Health, 2013
- High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional studyBMC Pediatrics, 2012
- Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational SettingsPLoS Medicine, 2012
- Regional Anthropometry Changes in Antiretroviral-Naïve Persons Initiating a Zidovudine-Containing Regimen in Mbarara, UgandaAIDS Research and Human Retroviruses, 2011
- Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224sClinical Infectious Diseases, 2011
- Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Women's Interagency HIV StudyAIDS Patient Care and STDs, 2009
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- Obesity among Patients with HIV: The Latest EpidemicAIDS Patient Care and STDs, 2008
- Lipoatrophy among HIV‐infected patients is associated with higher levels of depression than lipohypertrophyHIV Medicine, 2008
- Self-Perception of Body Fat Changes and HAART Adherence in the Women’s Interagency HIV StudyAIDS and Behavior, 2008